Ngā hua rapu - Richard D. DiMarchi

Whakamahine hua
  1. 1
    Fibroblast growth factor 21 night watch: advances and uncertainties in the field

    Fibroblast growth factor 21 night watch: advances and uncertainties in the field mā Alexei Kharitonenkov, Richard D. DiMarchi

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  2. 2
    Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety

    Peptide Conjugates with Small Molecules Designed to Enhance Efficacy and Safety mā Rongjun He, Brian Finan, John P. Mayer, Richard D. DiMarchi

    I whakaputaina 2019
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  3. 3
    Anti-obesity drug discovery: advances and challenges

    Anti-obesity drug discovery: advances and challenges mā Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, Richard D. DiMarchi

    I whakaputaina 2021
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  4. 4
    Anti-Obesity Therapy: from Rainbow Pills to Polyagonists

    Anti-Obesity Therapy: from Rainbow Pills to Polyagonists mā Timo D. Müller, Christoffer Clemmensen, Brian Finan, Richard D. DiMarchi, M. Tschöp

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  5. 5
    Optimization of the Native Glucagon Sequence for Medicinal Purposes

    Optimization of the Native Glucagon Sequence for Medicinal Purposes mā Joseph R. Chabenne, Maria A. DiMarchi, Vasily M. Gelfanov, Richard D. DiMarchi

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  6. 6
    Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology

    Peptide‐based multi‐agonists: a new paradigm in metabolic pharmacology mā Sara J. Brandt, Timo D. Müller, Richard D. DiMarchi, M. Tschöp, Kerstin Stemmer

    I whakaputaina 2018
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  7. 7
    Insulin analogues and their potential in the management of diabetes mellitus

    Insulin analogues and their potential in the management of diabetes mellitus mā Geremia B. Bolli, Richard D. Di Marchi, G. D. Park, Stig Pramming, Veikko A Koivisto

    I whakaputaina 1999
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  8. 8
    Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis

    Effect of targeted estrogen delivery using glucagon-like peptide-1 on insulin secretion, insulin sensitivity and glucose homeostasis mā Joseph P. Tiano, Chandra R. Tate, Bin Yang, Richard D. DiMarchi, Franck Mauvais‐Jarvis

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  9. 9
    Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes

    Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes mā Megan E. Capozzi, Richard D. DiMarchi, Matthias H. Tschöp, Brian Finan, Jonathan E. Campbell

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  10. 10
    The metabolic actions of glucagon revisited

    The metabolic actions of glucagon revisited mā Kirk M. Habegger, Kristy M. Heppner, Nori Geary, Timothy J. Bartness, Richard D. DiMarchi, Matthias H. Tschöp

    I whakaputaina 2010
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  11. 11
    Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment

    Gαs regulates Glucagon-Like Peptide 1 Receptor-mediated cyclic AMP generation at Rab5 endosomal compartment mā Shravan Babu Girada, Ramya S. Kuna, Shilpak Bele, Zhimeng Zhu, N.R. Chakravarthi, Richard D. DiMarchi, Prasenjit Mitra

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  12. 12
    Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice

    Contribution of brown adipose tissue activity to the control of energy balance by GLP-1 receptor signalling in mice mā Kristy M. Heppner, Sarah Marks, Jenna Holland, Nickki Ottaway, David L. Smiley, Richard D. DiMarchi, Diego Pérez–Tilve

    I whakaputaina 2015
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  13. 13
    Peptide lipidation stabilizes structure to enhance biological function

    Peptide lipidation stabilizes structure to enhance biological function mā Brian Ward, Nickki Ottaway, Diego Pérez–Tilve, Dejian Ma, Vasily M. Gelfanov, Matthias H. Tschöp, Richard D. DiMarchi

    I whakaputaina 2013
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  14. 14
    GLP-1/glucagon receptor co-agonism for treatment of obesity

    GLP-1/glucagon receptor co-agonism for treatment of obesity mā Miguel A. Sánchez-Garrido, Sara J. Brandt, Christoffer Clemmensen, Timo D. Müller, Richard D. DiMarchi, Matthias H. Tschöp

    I whakaputaina 2017
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  15. 15
    Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism

    Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism mā Piotr Mróz, Brian Finan, Vasily M. Gelfanov, Bin Yang, Matthias H. Tschöp, Richard D. DiMarchi, Diego Pérez–Tilve

    I whakaputaina 2018
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  16. 16
    GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications

    GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications mā Jonathan E. Campbell, Timo D. Müller, Brian Finan, Richard D. DiMarchi, Matthias H. Tschöp, David A. D’Alessio

    I whakaputaina 2023
    Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  17. 17
    Unimolecular Polypharmacy for Treatment of Diabetes and Obesity

    Unimolecular Polypharmacy for Treatment of Diabetes and Obesity mā Matthias H. Tschöp, Brian Finan, Christoffer Clemmensen, Vasily M. Gelfanov, Diego Pérez–Tilve, Timo D. Müller, Richard D. DiMarchi

    I whakaputaina 2016
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  18. 18
    Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes

    Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes mā Qiming Tan, Seun Akindehin, Camila E. Orsso, Richelle C. Waldner, Richard D. DiMarchi, Timo D. Müller, Andrea M. Haqq

    I whakaputaina 2022
    Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa
    Revisão
    Tiaki ki tētahi rārangi
    I tiakina i:
  19. 19
    A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia

    A glucagon analog chemically stabilized for immediate treatment of life-threatening hypoglycemia mā Joseph R. Chabenne, Maria DiMarchi Chabenne, Yan Zhao, Jay J. Levy, David L. Smiley, Vasily M. Gelfanov, Richard D. DiMarchi

    I whakaputaina 2014
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:
  20. 20
    Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice

    Monomeric GLP-1/GIP/glucagon triagonism corrects obesity, hepatosteatosis, and dyslipidemia in female mice mā Sigrid Jall, Stephan Sachs, Christoffer Clemmensen, Brian Finan, Frauke Neff, Richard D. DiMarchi, Matthias H. Tschöp, Timo D. Müller, Susanna M. Hofmann

    I whakaputaina 2017
    Whiwhi kuputuhi katoa
    Artigo
    Tiaki ki tētahi rārangi
    I tiakina i:

Ngā utauta rapu: